Alentis Therapeutics is a thriving clinical-stage biotech company in Basel, Switzerland, developing breakthrough treatments for organ fibrosis and CLDN1 positive tumors. The company, lead by CEO Dr. Roberto Iacone, was founded in 2019 and is based on groundbreaking research from the laboratory of Prof. Thomas Baumert – co-founder of Alentis – at the University of Strasbourg and the French National Institute of Health.
Today, Alentis Therapeutics raises $105M in a Series C funding round led by Jeito Capital, Novo Holdings and RA Capital Management. Current investors, including Pureos Bioventures – one of the partners of BaseLaunch which invested into Alentis since the Series A round – also participated. The company will use the proceeds to advance its clinical programs ALE.F02 and ALE.C04, both of which are first-in-class anti-Claudin-1 antibodies for organ fibrosis and CLDN1 positive tumors. The funding will also support the development of the platform to engineer CLDN1 antibody drug conjugates and bispecific antibodies.
CEO Dr. Roberto Iacone is delighted about the prospect of improving therapy for patients suffering from fibrotic diseases. “There are huge unmet needs in organ fibrosis and cancer,” he stated.
We are very proud to count Alentis Therapeutics among our portfolio companies, having been with them since the very beginning, and congratulate them warmly on achieving this brilliant milestone. With their financing round included, our portfolio has now collectively raised over $550M.
Read more in their press release over here: